Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients.

Listen to the full podcast episode to learn more.

Please see Important Safety Information for TAGRISSO.

Please see complete Prescribing Information, including Patient Information for TAGRISSO.

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO&reg; (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients.
Listen to the full podcast episode to learn more.
Please see <a href="https://www.fiercepharma.com/fiercepharmacom/important-safety-information-tagrisso">Important Safety Information</a> for TAGRISSO.
Please see complete <a href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/52503580-1192-44f7-a05e-5743159ed19b/52503580-1192-44f7-a05e-5743159ed19b_viewable_rendition__v.pdf">Prescribing Information</a>, including Patient Information for TAGRISSO.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Arun Krishna, VP and franchise head for an AstraZeneca US OBU, discusses a treatment option for patients.

An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what inspired the launch of ElevAAte—a new nonprofit founded this year to support and grow East Asian American leadership in the industry.

In this week’s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu speaks with two of ElevAAte’s co-founders: Architect Therapeutics CEO Angie You and Candid Therapeutics CEO Ken Song. The veteran biotech leaders discuss why a group like ElevAAte is needed and how East Asian Americans can harness their collective strength to build the next generation of biopharma executives.

You and Song—who led Amunix’s $1.2 billion sale to Sanofi and RayzeBio’s $4.1 billion acquisition by Bristol Myers Squibb, respectively—also share insights from their dealmaking careers and offer advice for young professionals entering the field.

To learn more about the topics in this episode: 
Though prevalent in the lab and middle management, East Asian Americans are underrepresented in biopharma C-suites: report
Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M
A reason to fight: Former FDA leader Janet Woodcock inspires 3rd Biotech Sisterhood summit
Takeda taps Julie Kim to take over for retiring CEO Christophe Weber

 

This episode is sponsored by Cencora. 

Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what inspired the launch of ElevAAte&mdash;a new nonprofit founded this year to support and grow East Asian American leadership in the industry.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu speaks with two of ElevAAte&rsquo;s co-founders: Architect Therapeutics CEO Angie You and Candid Therapeutics CEO Ken Song. The veteran biotech leaders discuss why a group like ElevAAte is needed and how East Asian Americans can harness their collective strength to build the next generation of biopharma executives.
You and Song&mdash;who led Amunix&rsquo;s $1.2 billion sale to Sanofi and RayzeBio&rsquo;s $4.1 billion acquisition by Bristol Myers Squibb, respectively&mdash;also share insights from their dealmaking careers and offer advice for young professionals entering the field.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/though-prevalent-lab-and-middle-management-east-asian-americans-are-underrepresented">Though prevalent in the lab and middle management, East Asian Americans are underrepresented in biopharma C-suites: report</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/candid-continues-t-cell-engager-shopping-spree-925m-biobucks-deal-wuxi-biologics">Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/biotech-sisterhood-annual-summit-features-fda-legend-janet-woodcock">A reason to fight: Former FDA leader Janet Woodcock inspires 3rd Biotech Sisterhood summit</a></li>
<li><a href="https://www.fiercepharma.com/pharma/takeda-tabs-julie-kim-take-over-retiring-ceo-christophe-weber">Takeda taps Julie Kim to take over for retiring CEO Christophe Weber</a></li>
</ul>
&nbsp;
This episode is sponsored by <a href="https://www.cencora.com/initiatives/pharma/supporting-biopharma-breakthroughs?utm_source=fiercepharma&amp;utm_medium=audio&amp;utm_campaign=gps_100_awareness&amp;utm_content=podcast">Cencora</a>.&nbsp;

ElevAAte and the push for East Asian American leaders in biopharma 

We’ve known for a while that there are two Anguses—both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the first time, we’re bringing them together for a “Variety Studio: Actors on Actors”-style conversation.

In this week’s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu and STAT Cancer Reporter Angus Chen share insights into their work covering cancer and their thoughts on racial identity during a tumultuous time.

They discuss what excites them most in the oncology field, how their reporting approaches differ and how they’ve often been mistaken for one another.

To learn more about the topics in this episode: 
Judge permanently blocks NIH grant caps, prompting HHS appeal
Cancer research, long protected, feels ‘devastating’ effects under Trump
As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says

We&rsquo;ve known for a while that there are two Anguses&mdash;both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the first time, we&rsquo;re bringing them together for a &ldquo;Variety Studio: Actors on Actors&rdquo;-style conversation.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu and STAT Cancer Reporter Angus Chen share insights into their work covering cancer and their thoughts on racial identity during a tumultuous time.
They discuss what excites them most in the oncology field, how their reporting approaches differ and how they&rsquo;ve often been mistaken for one another.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/judge-permanently-blocks-nih-grant-caps-decision-hhs-appealing">Judge permanently blocks NIH grant caps, prompting HHS appeal</a></li>
<li><a href="https://www.statnews.com/2025/03/24/trump-cancer-research-funding-cuts-patients-researchers-worried/">Cancer research, long protected, feels &lsquo;devastating&rsquo; effects under Trump</a></li>
<li><a href="https://www.fiercebiotech.com/cro/trump-targets-dei-4-pharmas-reaffirm-commitments-diversifying-clinical-trials">As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials</a></li>
<li><a href="https://www.fiercepharma.com/pharma/cell-and-gene-therapies-peter-marks-fda-exit-jolts-struggling-field-deep-uncertainty">For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty</a></li>
<li><a href="https://www.statnews.com/2025/01/31/car-t-cells-donate-protein-other-immune-cells-to-fight-cancer-study/">CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says</a></li>
</ul>

Angus on Angus: A Fierce oncology discussion

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are still scrambling to respond to mounting trade pressures. While many unknowns remain, biopharma companies should waste no time in starting to evaluate their options.  

In this week’s episode of “The Top Line,” we dig into the latest round of tariffs unveiled by the Trump administration and how they could impact multiple areas of the life sciences industry. Fierce Pharma’s Fraiser Kansteiner sits down with KPMG’s life sciences sector leader Kristin Pothier, who discusses how the current tariffs could pose challenges, how drugmakers and other life sciences companies should respond and whether additional sector-specific duties are on the horizon.  

To learn more about the topics in this episode: 
As Trump's 'Liberation Day' tariffs seem to spare pharmaceuticals, threat of industry-specific duties and loopholes persists
Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey
Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'
Trump again threatens tariffs on pharmaceuticals in 'not too distant' future

This episode is sponsored by Cencora.

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are still scrambling to respond to mounting trade pressures. While many unknowns remain, biopharma companies should waste no time in starting to evaluate their options.&nbsp;&nbsp;
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; we dig into the latest round of tariffs unveiled by the Trump administration and how they could impact multiple areas of the life sciences industry. Fierce Pharma&rsquo;s Fraiser Kansteiner sits down with KPMG&rsquo;s life sciences sector leader Kristin Pothier, who discusses how the current tariffs could pose challenges, how drugmakers and other life sciences companies should respond and whether additional sector-specific duties are on the horizon.&nbsp;&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/trumps-liberation-day-tariffs-seem-spare-pharma-threat-industry-specific-duties-and">As Trump's 'Liberation Day' tariffs seem to spare pharmaceuticals, threat of industry-specific duties and loopholes persists</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/biotechs-fear-trump-20-tariffs-will-drive-manufacturing-costs-hurt-medicine-access">Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey</a></li>
<li><a href="https://www.fiercepharma.com/pharma/lilly-ceo-ricks-trumps-tariffs-itll-be-hard-come-back-here">Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'</a></li>
<li><a href="https://www.fiercepharma.com/pharma/trump-again-threatens-tariffs-pharmaceuticals-not-too-distant-future">Trump again threatens tariffs on pharmaceuticals in 'not too distant' future</a></li>
</ul>
This episode is sponsored by <a href="https://www.cencora.com/initiatives/pharma/supporting-biopharma-breakthroughs?utm_source=fiercepharma&amp;utm_medium=audio&amp;utm_campaign=gps_100_awareness&amp;utm_content=podcast">Cencora</a>.

An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips